𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

✍ Scribed by Hagop M. Kantarjian; Jorge Cortes; Paul La Rosée; Andreas Hochhaus

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
270 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera

Significance of myelofibrosis in early c
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
✍ Hagop M. Kantarjian; Carlos E. Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract ## BACKGROUND Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. ## METHODS The current study evaluated the significance of the

Persistent neutropenia in chronic myelog
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.